

For Immediate Release:

November 10, 2009

Contact:

Mary Kuramoto

513-579-9911 x 2523

m.kuramoto@medpace.com**Medpace therapeutic expert, Charles Schmidt, MD, PhD to present at the Paediatric Drug Development and Clinical Trials in Brussels, November 17-18, 2009**

CINCINNATI, OH, (November 10, 2009) - Medpace, Inc., a leading global full-service clinical research organization, today announced that Charles Schmidt, MD, PhD, General Manager, Latin America, will speak at the Paediatric Drug Development and Clinical Trials Congress in Brussels in November 2009.

Topics for Dr. Schmidt's talk on conducting pediatric clinical trials in Latin America will include: outlining the regional expertise and benefits, identifying regulatory and bioethical aspects for consideration when running trials in Latin America, discussing efficient methods to identify appropriate sites, uncovering successful risk management strategies, and outlining opportunities and future trends in pediatric trials.

Latin America is considered a growth market for pharmaceuticals, offering an attractive [clinical development](#) environment based upon a number of factors. These factors include the presence of large treatment-naïve patient populations, well-trained and qualified medical personnel, and the ability to recruit patients six months out of phase with North America, allowing 12 month patient recruiting for multi-national trials.

Dr. Schmidt possesses a wealth of experience as a clinical developer and [regulatory expert](#) in all trial phases in Latin America, having led trials with other US based CROs. Dr. Schmidt is the founder and former president of the Brazilian Association of CROs (ABRACRO), and the Vice Coordinator of the post-graduate program of the Santa Casa Medical School in São Paulo, one of the top medical schools in Latin America. Dr. Schmidt has directed clinical operations across Brazil, Argentina, Chile, Peru, Central America, and Mexico.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009, CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 1,000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-

IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from [Medpace Reference Laboratories](#), complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and centralized imaging core laboratory management and reading from Imagepace.

Visit the Medpace website at www.medpace.com